Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Addition of TACE Use for Farmorubicin to Be Reported to PAFSC Second Committee
October 7, 2013
- NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
- PMDA Considers Offering Development Strategy Consultations to Drug Makers: Office Director
October 3, 2013
- Industrial Competitiveness Council Finalizes Enforcement Policy for New Growth Strategy; Recommends Name for Japanese Version of NIH
October 3, 2013
- PMDA Branch in Kansai Region Officially Opens
October 2, 2013
- Interim Report of Diovan Panel Fails to Lay Bare Who Altered Data, for What Purpose
October 1, 2013
- MHLW to Strengthen Measures Against Improper Research Practices from FY2014; Surprise Inspections Also Planned
October 1, 2013
- Health Ministry Approves Sovriad, Hizentra
September 30, 2013
- Incentives to Promote the Use of Generic Drugs by DPC Hospitals Being Discussed: Director Utsunomiya of MED
September 30, 2013
- TPP Partners Likely to Accept Japanese Proposal on Data Exclusivity Period: Mr Eto of LDP
September 30, 2013
- Japan Health Minister Meets Exec of Swiss Novartis, Seeks Cooperation in Diovan Probe
September 27, 2013
- Global Simultaneous Development Likely to Expand with Premium for New Drug Development: PhRMA
September 27, 2013
- CSIMC Subcommittee Recommends Addition of Consumption Tax to Actual Market Prices, Will Continue Discussing Method for Clearly Specifying Added Tax
September 27, 2013
- JPWA Seeks Generic Name Listing for Wider Range of Generics
September 27, 2013
- FPMAJ Opposes Removing Exceptions for 80% Pricing Rule for Racemic Body-Derived Drugs
September 26, 2013
- Mixed Healthcare Using Unapproved Drugs Proposed for Special Zone
September 26, 2013
- Health Ministry Approves 28 Products including Oblean, Kadcyla
September 26, 2013
- Discussions on Reform of the High-cost Healthcare Benefit System on the Horizon; Will It Be Possible to Reduce Drug Copayments?
September 25, 2013
- Japan Needs Generic Drug Makers that Can Compete in the Global Market: Director Jo of EAD
September 25, 2013
- Regulatory Reform Council Sets Out Policies to Monitor Ministries’ Deregulation Efforts
September 24, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…